A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
**Temporarily Closed to Accrual – Effective August 15, 2009**
**Cohort A Permanently Closed to Accrual – Effective August 15, 2009**
**Re-Open to Accrual – Effective October 1, 2009**
**Cohort B Temporarily Closed to Accrual Effective – Effective July 29, 2011**
**Cohort B reopened at Select Institutions – effective August 30, 2011**
**Cohort B Permanently Closed to Accrual – Effective December 20, 2011** 

A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed By Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 positive operable breast cancer
**Closure to Accrual – Effective December 15, 2011** 

A Randomized Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller
**Closed to Accrual - effective January 22, 2010** 

A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) 

A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer 

A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS)
**COMPLETED (No Further Activity is being Conducted), as of February 27, 2006** 

A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

**Notice of Suspension of CALGB-SWOG C80405 as of June 6, 2008-Only patients who have been consented to this study on or before, FRIDAY, JUNE 6, 2008, will be allowed to enroll on CALGB/SWOG C80405.**

**Effective November 7, 2008, CALGB/SWOG 80405, has been reactivated and is open to patient accrual.**

**Effective November 17, 2008, CALGB/SWOG 80405, has been temporarily closed to patient accrual.**

**Effective December 12, 2008, CALGB/SWOG 80405, has been Reactivated.**

**Closed to Pre-Registration of New Patients – Effective February 15, 2012**

**Closed to Registration and Randomization of New Patients – Effective March 1, 2012** 

A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
**Closed to Accrual – Effective July 3, 2009** 

A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM, Oblimersen Sodium, NSC #683428, IND #58842), A BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years
**Closed to Accrual – Effective October 20, 2006** 

A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease
**Closed to Accrual - effective January 5, 2010** 

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
** Closed to Accrual Effective – October 15, 2011** 

A Phase II Study Of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 50 Years with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia By CALGB, ECOG and SWOG 

A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (< 2 Cm) Peripheral Non-Small Cell Lung Cancer 

Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control, OPEC)
**Closed to Accrual – Effective December 28, 2004**
**COMPLETED (No Further Activity is being Conducted), as of June 2, 2010** 

A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data
**Temporary Suspension to Accrual - Effective July 22, 2010**

**Reactivation: Open to Accrual– Effective October 5, 2010**

**Closure to Accrual – Effective November 30, 2011** 

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer 

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide 

A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer 

Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) As Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
**Closed to Accrual - Effective July 30, 2010** 

Endocrine Therapy With Or Without Inhibition Of EGF And HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of Fulvestrant With Or Without Lapatinib (GW572016) For Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
**Closed to Accrual - Effective July 14, 2010** 

A Randomized Phase III Trial Of Weekly Paclitaxel Compared To Weekly Nanoparticle Albumin Bound Nab-Paclitaxel Or Ixabepilone With Or Without Bevacizumab As First-Line Therapy For Locally Recurrent Or Metastatic Breast Cancer
**Notice of Suspension of Accrual for Arm C – Effective July 8, 2011**

**Permanently Closed to Accrual—Effective November 30, 2011** 

Endocrine Therapy with or without ANTI-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer
**Closure to Accrual – Effective November 30, 2011** 

Randomized Phase III Trial of Paclitaxel combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
**Closed to Accrual – Effective February 29, 2012** 

A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA, IIIB or Regional Stage IV Breast Cancer
**ADMINISTRATIVELY COMPLETED as of December 15, 2002** 

A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil – (CMF) or Doxorubicin and Cyclophosphamide – (AC), Versus Capecitabine in Women 65 Years and Older with Node Positive or High-Risk Node Negative Breast Cancer
**Closed to Accrual – Effective December 29, 2006** 

Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas 

Quality of Life, Employment, and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101
**Closed to Accrual – Effective July 30, 2010** 

Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma
**Closed to Accrual – Effective May 29, 2009** 

A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
**Permanently Closed to new patient accrual - Effective January 15, 2005** 

A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704865 IND# 7921) Versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer
**Closed to Accrual – Effective April 14, 2006**
**COMPLETED (No Further Activity is being Conducted), as of October 22, 2010** 

A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer 

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients with Advanced Hepatocellular Carcinoma (HCC) 

A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine as Adjuvant Treatment After Cystectomy for Transitional Cell Carcinoma of the Bladder
**Closed to Accrual – Effective July 15, 2005**
**COMPLETED (No Further Activity is being Conducted), as of October 6, 2010** 

A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors
**ADMINISTATIVELY COMPLETED as of April 1, 2005** 

A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
**Closed to Accrual – Effective April 4, 2012** 

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer 

A Randomized Phase III Trial of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma
**Closed to Accrual – Effective July 1, 2005** 

A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer
**Closed to Accrual – Effective December 21, 2007** 

A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, And Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma 

Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors 

A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
**Closed to Accrual - effective October 28, 2009** 

A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion 

A Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With States III/IV Head and Neck Squamous Cell Carcinoma
**Closed to Accrual - Effective December 20, 2004**
**COMPLETED (No Further Activity Being Conducted) as of November 25, 2009** 

Phase III Randomized, Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, gefitnib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer
**Partial closure: Arm C (step 2) has been permanently closed as of 8/22/07**

**Closed to Accrual – Effective November 13, 2008** 

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer 

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>= 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC) 

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma 

Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA after Hormonal Therapy for Prostate Cancer
**Closed to Accrual – Effective December 28, 2004, **
**COMPLETED (No Further Activity is being Conducted), as of February 4, 2010** 

A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose- Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
**Accrual Suspended as of Feb 16, 2008 - No new patients should be enrolled into this study** **RE-OPENED TO ACCRUAL, as of April 29, 2008** **ClOSED TO ACCRUAL, as of November 17, 2008**  

A Randomized Phase III Trial of Thalidomide (NSC #66847) Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma
**Closed to Accrual – Effective April 18, 2003**

**COMPLETED (No Further Activity Being Conducted) as of April 25, 2012** 

Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) - Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction

**Closed to Accrual – Effective May 7, 2010** 

An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid TM) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy

** Closed to Accrual Effective – November 30, 2011** 

Master Protocol for Pharmacogenetic and Genomic Studies.
**Closed to Accrual – Effective October 15, 2008* 

A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
**Closed to Accrual – Effective May 26, 2004** 

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer 

Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma
**Closed to Accrual, Effective May 2, 2006**
**COMPLETED (No Further Activity is being Conducted), as of June 2, 2010** 

A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
**Closed to Accrual - effective April 22, 2008** 

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
**Closed to Accrual – effective September 1, 2010** 

A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients over Age 60 in First Remission
**CTSU Re-Activation Date: 2/7/08**
**Closed to Accrual - effective December 7, 2009** 

A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
**Temporary Suspension of Accrual – effective September 24, 2010**
**Re-Open to Accrual – effective February 4, 2011** 

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) 

Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin versus Oxaliplatin, Fluorouracil and Leucovorin versus Bevacizumab Alone in Previously Treated Patients with Advanced Colorectal Cancer
**COMPLETED (No Further Activity is being Conducted) as of April 20, 2007** 

Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin Vs Oxaliplatin, 5-Fluorouracil and Leucovorin Vs 5-Fluorouracil and Leucovorin For Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil
**Closed to Accrual – Effective November 1, 2005** 

CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer 

A Randomized, Placebo-controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts
**Closed to Accrual – Effective September 15, 2005**

**ECOG has Discontinued Activation of any New Sites to this Study - Effective April 19, 2005**

**COMPLETED (No Further Activity Being Conducted) as of April 30, 2012** 

Randomized Phase III Trial of Lenalidomide versus Observation Alone In Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
**Accrual Suspended - Effective December 16, 2011** 

Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas 

A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer
**Closed to Accrual – Effective December 15, 2005**
**COMPLETED (No Further Activity Being Conducted) as of December 28, 2010** 

Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin''s Lymphoma
** Closed to Accrual - Effective September 12, 2008 ** 

Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC
**Closed to Accrual – Effective April 7, 2004**
**COMPLETED (No Further Activity Being Conducted) as of December 8, 2010** 

A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders
**Suspended to Accrual – Effective September 14, 2005**
**Reactivated to Accrual – Effective November 23, 2005**
**Closed to Accrual - Effective June 1, 2007** 

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation 

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
**Enrollment SUSPENSION – Effective September 24, 2009**

**RE-OPEN TO ACCRUAL EFFECTIVE December 18, 2009**

**Step 1 Closure to Accrual – Effective February 28, 2011** 

A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
**Suspension of Accrual – Effective April 29, 2009**

**Re-Open to Accrual – Effective August 10, 2009**

**Suspension of Accrual – Effective October 7, 2010**

**Closure to Accrual – Effective February 11, 2011** 

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation
**Closed to Accrual – Effective April 29, 2009** 

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC 

A Phase III, Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC 266046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma
**COMPLETED (No Further Activity is being Conducted), as of February 4, 2008** 

Program For The Assessment of Clinical Cancer Test (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
**Closed to Accrual – Effective October 6, 2010** 

A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902) 

A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma after First Line Chemotherapy
**Closed to Accrual – Effective July 23, 2007**
**COMPLETED (No Further Activity Being Conducted) as of June 6, 2011** 

Treatment of Patients with Stage IB2 Carcinoma of the Cervix A Randomized Comparison of Radical Hysterectomy and Tailored Radiation Versus Primary Chemo Radiation
**COMPLETED (No Further Activity Being Conducted) as of April 28, 2005** 

A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix
**Closed to Accrual – Effective April 30, 2007**
**COMPLETED (No Further Activity Being Conducted) as of June 13, 2011** 

Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
**SUSPENSION OF ENTRY TO PATIENTS WITH PRIOR EXTERNAL RADIATION THERAPY, EFFECTIVE 7/23/2007 ** **RE-ENTRY OF SUBJECTS WITH PRIOR EXTERNAL RADIATION THERAPY, EFFECTIVE 2/11/2008**
**Closed to Accrual – Effective April 20, 2009** 

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT 2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy 

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer 

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #113912) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
**Suspension of Accrual – Effective June 29, 2009**
**Closed to Accrual – Effective August 10, 2009** 

A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (#46525) and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis
**Study Suspended to Patient Entry effective September 1, 2009**
**Closed to Accrual - effective September 1, 2009** 

: A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #113912) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
**Closed to Accrual – Effective January 3, 2012** 

A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) 

A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma 

A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865, IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865, IND #113912) 

A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865, IND #113912))
**Closed to Accrual—Effective November 30, 2011** 

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma 

A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary 

GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #113912) in the Treatment of Primary Stage II, III OR IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262
**Suspended to Patient Entry – Effective February 8, 2012**

**Re-opened patient entry - Effective April 30, 2012** 

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy 

A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

**Suspension of Accrual – Effective Friday June 6, 2008**

**Study will Re-Open to Accrual – Effective August 18, 2008 **

**Effective October 24, 2008 at 8:00 AM CDT accrual of patients 70 years of age and older is temporarily suspended.** **

**Effective May 8, 2009, NO147 will reopen to accrual of patients 70 years of age and greater.**

**Closed to Accrual - effective November 25, 2009** 

The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27

**Closed to Accrual - Effective July 31, 2008** 

Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases 

Phase III Intergroup Study of Radiotherapy versusTemozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide forPatients with 1p/19q Codeleted Anaplastic Glioma
**Temporarily Closed to Accrual - Effective December 20, 2011** 

MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation Study of Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed versus Erlotinib.
**Closed to Accrual - effective November 13, 2009** 

Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer 

A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision 

A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease 

A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases
**Closed to Accrual – Effective June 19, 2009**
**COMPLETED (No Further Activity is being Conducted), as of January 29, 2010** 

A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer
**Closed to Accrual – Effective April 22, 2005, **

**Accrual on Hold Unitl Further Notice-Effective April 15, 2005**

**COMPLETED (No Further Activity Being Conducted) as of January 6, 2012** 

A Randomized Phase III Trial of Exemestane Versus Anastrozole in PostMenopausal Women With Receptor Positive Primary Breast Cancer
**Closed to Accrual – Effective July 31, 2008**
**COMPLETED (No Further Activity Being Conducted) as of June 13, 2011** 

The Influence of Five Years of Adjuvant Anastrozole or Exemestane on bone Mineral Density in Postmenopausal Women with Primary Breast Cancer - A Companion Study to NCIC CTG MA.27
**Closed to Accrual – Effective May 30, 2008**
**COMPLETED (No Further Activity Being Conducted) as of July 8, 2011** 

A Phase III Randomized Trial Of Metformin Versus Placebo On Recurrence And Survival In Early Stage Breast Cancer
**Suspension of Accrual – Effective August 31, 2010**
**Re-Activation for US Participation – Effective May 13, 2011 **
**Closure to Accrual to Quality of Life, Physical Activity, and Diet Questionnaires – Effective November 4, 2011** 

A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer (START)
**Closed to Accrual – Effective May 13, 2011 ** 

A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3N0-1M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy
**Closed to Accrual – Effective October 14, 2003**

**COMPLETED (No Further Activity is being Conducted), as of March 30, 2011**
 

A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy
**Closed to Accrual – Effective March 31, 2004 ** 

A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy
**Closed to Accrual – Effective June 15, 2006** 

A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-Negative Breast Cancer
**Closed to Accrual – Effective July 25, 2008** 

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)
**Closed to Accrual – Effective May 3, 2007** 

A Randomized Phase III Trial of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
** Closure of Accrual to BAHO Substudy: Quality of Life (QOL), Cosmesis, and Digital Photos Assessments– Effective May 28, 2009** 

A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
**Closed to Accrual - Effective June 30, 2010** 

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
**Closed to Accrual - effective January 6, 2010** 

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy 

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer 

A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon
**Closed to Accrual – Effective October 6, 2006** 

A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine, and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients with Resected or Ablated Liver Metastases from Colorectal Cancer.
**ADMINISTRATIVELY COMPLETED as of July 28, 2009** 

A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients with Potentially Resectable Hepatic Colorectal Metastases
**Suspension of Accrual – Effective October 8, 2010**

**Re-Activation of Accrual – Effective February 3, 2011 **

**Closed to Accrual—Effective December 16, 2011**

**COMPLETED (No Further Activity Being Conducted) as of April 9, 2012** 

Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer 

A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum
**Closed to Accrual - Effective August 16, 2010** 

A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126/Dev. 1077)
** Closed to Accrual – Effective August 20, 2008 ** 

A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease)for Advanced Head and Neck Carcinomas
**Closed to Accrual – Effective June 23, 2005** 

A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer
**Closed to Accrual – Effective August 30, 2007** 

A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma
**Closed to Accrual – Effective February 8, 2012** 

A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus with Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Brain Metastases
**Closed to Accrual – effective August 11, 2009** 

Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer
**Completed (No Further Activity Conducted) – Effective January 2009** 

A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer
**Closed to Accrual - effective November 6, 2009** 

A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone.
****ADMINISTRATIVELY COMPLETED as of October 14, 2009** ** 

A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery
**Temporary Closure to Accrual – Effective June 2, 2011**
**Reactivated to Accrual – Effective July 25, 2011** 

A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
**Closed to Accrual – August 21, 2009** 

A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] For Stage III and IV Head and Neck Carcinomas
**Closed to Accrual – Effective March 3, 2009** 

Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma
**Closed to Accrual – effective June 13, 2008** 

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
**Closed to Accrual to Substudy: Health-Related Quality of Life (QOL) - Effective March 22, 2012** 

A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
**Arms B and D Closed to Accrual – Effective June 17, 2011**
**Closure to Accrual – Effective November 22, 2011** 

Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy 

A Phase III Prospective Randomized Trial Of Dose-Escalated Radiotherapy With Or Without Short-Term Androgen Deprivation Therapy For Patients With Intermediate-Risk Prostate Cancer
**Closed to Accrual to Substudy: Health-Related Quality of Life (QOL) - Effective March 22, 2012** 

Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and AdjuvantTemozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with newly Diagnosed Glioblastoma
**Closed to Accrual – Effective May 11, 2011 ** 

RTOG 0848 A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma 

A Phase III Study of Postoperative Radiation Therapy (Imrt) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer 

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial 

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer 

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma 

Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer 

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 For Men with High Risk Prostate Cancer 

A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases
**Completed (No Further Activity Conducted) - Effective May 1, 2008** 

A Phase III Randomized Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer
**ADMINISTRAVELY COMPLETED as of May 7, 2004** 

A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade with Delayed Chemotherapy
**ADMINISTRATIVELY COMPLETED as of February 4, 2005** 

A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer
**Closed to Accrual – Effective December 1, 2005,**

**COMPLETED (No Further Activity Being Conducted) as of February 23, 2012** 

A Phase III Trial of Cisplatin/Etoposide/ Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
**Closed to Accrual – Effective April 15, 2005**
**COMPLETED (No Further Activity Being Conducted) as of December 9, 2010** 

A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)
**Closed to Accrual – Effective August 20, 2009** 

Randomized Phase III Trial of Cisplatin (NSC-119875) and Irinotecan (NCSC-616348) Versus Cisplatin and Etoposide (NSC-141540) in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)
**Closed to Accrual - Effective March 1, 2007**
**COMPLETED (No Further Activity is being Conducted), as of July 22, 2010** 

A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
**Closed to Accrual – Effective December 15, 2005**
**COMPLETED (No Further Activity Being Conducted) as of August 23, 2011** 

A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer
**Closed to Accrual – Effective April 1, 2006**
**COMPLETED (No Further Activity Being Conducted) as of August 30, 2011** 

Phase III Trial of Continuous Schedule AC+G Vs. Q2Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
** Suspension of Accrual – Effective November 10, 2010**
** Reactivation of Accrual – Effective December 15, 2010**
**Closed to Accrual – Effective January 15, 2012** 

Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
**The pharmacokinetic (PK) component (see Section 15.5) for SWOG S0226 has been permanently closed effective April 16, 2009**
**Closed to Accrual – Effective July 1, 2009** 

Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix
**COMPLETED (No Further Activity Conducted) - Effective July 28, 2003** 

Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant
**Closed to Accrual – Effective May 11, 2007** 

A Phase III Study of FOLFOX6 versus CapOX, with Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients with Previously Untreated Metastatic Colorectal Cancer
**ADMINISTRATIVELY COMPLETED as of 1/1/07** 

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
**Closed to Accrual – effective February 1, 2010** 

Myeloma Specimen Repository Protocol Ancillary
**Closed to Accrual – Effective November 1, 2010**
**COMPLETED (No Further Activity Being Conducted) as of June 13, 2011** 

"Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma"

**COMPLETED (No Further Activity Being Conducted) as of June 15, 2007 **  

A Phase III Blinded Study Of Immediate Post TURBT Instillation Of Gemcitabine Versus Saline In Patients With Newly Diagnosed Or Occasionally Recurring Grade I/II Superficial Bladder Cancer 

A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane and Trastuzumab Combination Therapy - Phase III
**COMPLETED (No Further Activity Being Conducted) as of February 1, 2006** 

Phase III Study Of Docetaxel And Atrasentan Versus Docetaxel And Placebo For Patients With Advanced Hormone Refractory Prostate Cancer.
**Closed to Accrual – effective May 1, 2010** 

A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, With and Without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients with Advanced Oropharyngeal Squamous Cell Cancer

**ADMINISTRATIVELY COMPLETED - Effective December 17, 2007** 

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment

**Closed to Accrual – Effective March 15, 2012** 

A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
**Closed to Accrual - Effective October 1, 2009** 

Phase III Prospective Randomized Comparison of Depot Octreotide plus interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC 704865) in Advance, Poor Prognosis Carcinoid Patients 

A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
**Closed to Accrual - Effective May 27, 2010** 

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX
**Suspension of Accrual - effective June 6, 2008**

**Reactivation of Accrual - effective October 15, 2009**

**Closed to Accrual – Effective November 10, 2010** 

A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant
**Study is Re-Activated and open to enrollment as of July 1, 2008**
**Closed to Accrual – Effective February 1, 2012** 

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) 

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study 

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less 

A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer 

Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary
**Closed to Accrual – Effective January 1, 2012**

**COMPLETED (No Further Activity Being Conducted) as of April 18, 2012** 

Lung Cancer Specimen Repository Protocol Ancillary
**Closed to Accrual – effective March 15, 2010**
**COMPLETED (No Further Activity is being Conducted), as of September 27, 2010** 

Cytogenetic Studies in Leukemia Patients
**Closed to Accrual – Effective January 1, 2012**

**COMPLETED (No Further Activity Being Conducted) as of April 18, 2012**